Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Blood Advances|September 15, 2021
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro, et al.
Cancers|July 2, 2021
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibFrancesca Romana Mauro, Diana Giannarelli, Andrea Visentin, et al.
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Blood Advances|June 12, 2025
Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control StudyAlberto Fresa, Idanna Innocenti, Annamaria Tomasso, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
Blood Advances|April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohortAndrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Haematologica|June 26, 2025
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, et al.
Blood Advances|January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian CohortEnrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Pageof 5